News on immunohistochemistry and other tissue-based testing methods.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.
PGDx and KingMed plan to provide tumor mutational burden testing to pharmaceutical companies for clinical trials in China and Hong Kong.
In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.
The firm sees the Phenoptics system as a highly automated, high-throughput imaging platform that can be used to translate discoveries made on its CODEX device.
